(DYN) Dyne Therapeutics - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.817m USD | Total Return: 23.2% in 12m
Avg Turnover: 27.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 50.2% YoY
Interest Coverage Ratio -42.7 is critical
Fakeout Volatile
Tailwinds
No distinct edge detected
Dyne Therapeutics, Inc. is a clinical-stage biotechnology firm headquartered in Waltham, Massachusetts, specializing in the development of targeted therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to engineer treatments for conditions including Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Dystrophy (FSHD).
Operating within the biotechnology sector, Dyne’s business model is characterized by high research and development intensity and a focus on precision medicine to address rare muscle, cardiac, and metabolic disorders. Clinical-stage biotech companies typically rely on the successful progression of candidate molecules through regulatory trial phases before achieving commercial revenue.
Investors may find ValueRays comparative data useful for evaluating Dynes pipeline against industry peers. The company’s focus remains on delivering disease-modifying payloads directly to skeletal, smooth, and cardiac muscle tissue to improve patient outcomes in underserved therapeutic areas.
- FORCE platform clinical trial data readouts drive investor sentiment and valuation
- FDA regulatory milestones for DM1 and DMD programs determine market entry
- Capital expenditure and cash burn rates impact future equity dilution risk
- Competition from established gene therapy firms affects long-term market share potential
- Strategic partnerships and licensing agreements provide critical non-dilutive funding sources
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 6.39 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -442.2m > Net Income -451.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 19.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (165.0m) vs 12m ago 50.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.22%; Δ -0.22% > 0%) |
| Interest Coverage Ratio: -42.67 > 6 (EBIT TTM -443.5m / Interest Expense TTM 10.4m) |
| A: 0.90 (Total Current Assets 1.02b - Total Current Liabilities 51.2m) / Total Assets 1.08b |
| B: -1.40 (Retained Earnings -1.52b / Total Assets 1.08b) |
| C: -0.49 (EBIT TTM -443.5m / Avg Total Assets 900.5m) |
| D: 4.03 (Book Value of Equity 865.1m / Total Liabilities 214.9m) |
| Altman-Z'' = 2.23 = BBB |
As of June 12, 2026, the stock is trading at USD 17.95 with a total of 1,593,779 shares traded.
Over the past week, the price has changed by -2.50%,
over one month by -2.76%,
over three months by -10.21% and
over the past year by +23.20%.
Dyne Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy DYN.
- StrongBuy: 7
- Buy: 6
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 38.3 | 113.1% |
P/B = 3.5163
P/EG = 0.19
Revenue TTM = 0.0 USD
EBIT TTM = -443.5m USD
EBITDA TTM = -441.4m USD
Long Term Debt = 149.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.03m USD (from shortTermDebt, last quarter)
Debt = 173.7m USD (corrected: LT Debt 149.4m + ST Debt 5.03m) + Leases 19.3m
Net Debt = -710.6m USD (calculated: Debt 173.7m - CCE 884.4m)
Enterprise Value = 2.11b USD (2.82b + Debt 173.7m - CCE 884.4m)
Interest Coverage Ratio = -42.67 (Ebit TTM -443.5m / Interest Expense TTM 10.4m)
EV/FCF = -4.97x (Enterprise Value 2.11b / FCF TTM -423.7m)
FCF Yield = -20.11% (FCF TTM -423.7m / Enterprise Value 2.11b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.05m) / Revenue TTM)
Tobins Q-Ratio = 1.95 (Enterprise Value 2.11b / Total Assets 1.08b)
Interest Expense / Debt = 5.98% (Interest Expense 10.4m / Debt 173.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -350.3m (EBIT -443.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.46 (Total Current Assets 1.02b / Total Current Liabilities 62.0m)
Debt / Equity = 0.20 (Debt 173.7m / totalStockholderEquity, last quarter 865.1m)
Debt / EBITDA = 1.61 (negative EBITDA) (Net Debt -710.6m / EBITDA -441.4m)
Debt / FCF = 1.68 (negative FCF - burning cash) (Net Debt -710.6m / FCF TTM -423.7m)
Total Stockholder Equity = 775.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.16% (Net Income -451.7m / Total Assets 1.08b)
RoE = -58.28% (Net Income TTM -451.7m / Total Stockholder Equity 775.1m)
RoCE = -47.97% (EBIT -443.5m / Capital Employed (Equity 775.1m + L.T.Debt 149.4m))
RoIC = -33.89% (negative operating profit) (NOPAT -350.3m / Invested Capital 1.03b)
WACC = 11.39% (E(2.82b)/V(2.99b) * Re(11.80%) + D(173.7m)/V(2.99b) * Rd(5.98%) * (1-Tc(0.21)))
Discount Rate = 11.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 55.19%
[DCF] Fair Price = unknown (Cash Flow -423.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.41 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.75 | Chg30d=+6.01% | Revisions=+0% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.76 | Chg30d=+4.40% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.08 | Chg30d=+3.40% | Revisions=+6% | GrowthEPS=+11.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.98 | Chg30d=+1.76% | Revisions=-20% | GrowthEPS=+3.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -20%